Most GLP-1 conversations assume a patient with significant weight to lose. The trials that anchor the public conversation — STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide — were built around exactly that patient: meaningful caloric deficit, high weekly target dose, sustained over 60 to 72 weeks.
This article is about the other patient. Already lean or near a healthy BMI. Trains consistently. Wants to refine body composition rather than reset it. The protocol that serves them is not "the same trial dose, just for less time" — it is a different goal, calibrated to a different signal, with a different dose.
Different goal, different dose
The published high-dose GLP-1 trials are unambiguous about what their protocols target. STEP 1 escalated semaglutide to a 2.4 mg weekly target dose over 16 weeks and reported a mean body-weight change of −14.9% versus −2.4% with placebo across 68 weeks.1 SURMOUNT-1 escalated tirzepatide to as much as 15 mg weekly and reported up to −20.9% at the highest dose over 72 weeks.2 Those numbers describe what the medications can do for the trial population — adults with obesity, or with overweight plus a weight-related complication.
Microdosing is a different question. The patient is not chasing a 15% scale loss. They are trying to nudge body composition — slightly less visceral fat, slightly more lean retention during a recomposition phase — without the appetite suppression and gastrointestinal disruption that come with full-dose protocols. That changes the dose, the cadence, and what success looks like.
The off-label clinical context
Off-label prescribing — using a medication for an indication or population not specifically listed on the FDA-approved label — is a routine, legal practice in US medicine. Roughly one in five US prescriptions is written off-label, and obesity-medicine practice guidelines explicitly contemplate clinician-determined protocols that fall outside trial-population labeling.3 The decision is the prescribing clinician's, made individually based on the patient's history, goals, and labs.
Compounded GLP-1 medications add a second layer of clinical context. Compounded preparations are made by licensed 503A pharmacies in response to a specific patient's prescription. They use the same active peptide as the FDA-approved branded versions, but compounded preparations are not themselves FDA-approved. The clinician determines whether a compounded protocol is appropriate, whether the dose is microdose or standard, and whether the patient is a candidate at all.
What this means for the patient considering a microdose: the protocol is not a self-service pricing tier. It is a physician-determined, physician-titrated, physician-monitored arrangement. The dose is set by the clinician, not the patient.
What microdosing actually looks like
A microdose protocol typically starts well below the trial-dose escalation curve and stays there. The clinician is not titrating up to a target dose; they are titrating to the lowest weekly amount that produces a small, sustainable appetite signal. Some patients hold at the starting dose indefinitely. Others step up by a fraction of the standard increment. Many never see a dose that approaches the trial targets.
The day-to-day experience is also different. Standard-dose patients commonly report meaningful nausea during dose escalation and a clear reduction in interest in food. Microdose patients more often describe a quieter version of that signal — they finish meals sooner, they do not graze as much in the evening — without the intensity of the high-dose response.
The cadence of clinical contact is similar to standard protocols: regular check-ins, dose reviews based on patient-reported response, and adjustments calibrated to composition signals rather than to a target dose.
Who this fits — and who it does not
Microdosing tends to fit patients who:
- Are already lean or near a healthy BMI
- Train consistently — strength, conditioning, or sport
- Want to refine composition rather than reset it
- Are willing to monitor signals other than the scale (waist, training quality, recovery)
It is often paired with a foundational peptide protocol — NAD+, sermorelin, or B12/MIC — so the recomposition signal is supported by recovery and energy work, not just appetite suppression.
It is not a fit for patients whose clinical picture calls for significant weight loss. Those patients are better served by standard-dose protocols, where the dose-response data is much stronger and the outcomes are well-characterized. A clinician will make this call during intake based on goals, medical history, and labs.
Compounded GLP-1 medications are also not appropriate for patients with certain thyroid conditions, pancreatitis history, or other contraindications. Eligibility is determined individually by the prescribing clinician.
How a clinician monitors composition
Because the goal is composition rather than scale, the monitoring cadence emphasizes what the scale does not capture:
- Waist circumference — the simplest visceral-fat proxy a patient can self-track at home
- Resting heart rate trends — recovery and training response
- Training session quality — load tolerance, perceived exertion, recovery time
- Patient-reported energy and recovery — sleep, hunger pattern, mood
The scale is still tracked, but it is not the primary signal. A steady — or even slightly rising — scale weight with measurable composition change is a desirable outcome on this protocol, not a failure. Conversely, a fast scale drop on a microdose protocol is a flag, not a win: it can mean the dose is too high for the patient's goal, or that lean tissue is being lost alongside fat.
Dose adjustments are conservative. The clinician would rather hold a low dose for an extra cycle than escalate prematurely and create the appetite suppression that defeats the protocol's purpose.
How TelePeptide handles this
Microdose GLP-1 protocols sit inside the Tone & Recompose track. Eligibility is reviewed individually by a licensed clinician based on goals, training pattern, and medical history. Pricing is the same locked-in founder rate as the standard-dose program — the clinician determines dose, not the price tier.
Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.
Footnotes
-
Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384, 989–1002. DOI:10.1056/NEJMoa2032183. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 ↩
-
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387, 205–216. DOI:10.1056/NEJMoa2206038. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 ↩
-
Garvey WT, Mechanick JI, Brett EM, et al. (2016). American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice 22 (Suppl 3). DOI:10.4158/EP161365.GL. ↩
FAQ
Common questions
What is microdosing GLP-1, in plain terms?
A low weekly dose of semaglutide or tirzepatide — typically a fraction of the standard escalation curve — used to nudge appetite without producing the strong gastrointestinal side effects of high-dose protocols. The goal is sustainable composition change, not rapid weight loss.
Why would a non-obese patient consider a GLP-1 at all?
For body recomposition: slightly less visceral fat, better lean retention during a recomp phase. Microdose protocols are designed for patients who are already lean or near a healthy BMI but want to refine composition. Eligibility is determined individually by a clinician.
How is the dose calibrated?
The clinician titrates to the lowest weekly dose that produces a small, sustainable appetite signal. Many patients hold at the starting dose indefinitely; some step up by a fraction of the standard increment. The approach is conservative — the clinician would rather hold a low dose for an extra cycle than escalate prematurely.
Is microdosing off-label?
Compounded GLP-1 medications are prescribed individually based on medical necessity. Compounded medications are not FDA-approved. The approach is physician-supervised at every step, with the clinician determining whether microdose, standard-dose, or no GLP-1 is appropriate.
What does success look like on a microdose protocol?
Composition signals — waist circumference, training capacity, energy, recovery — rather than scale change. A flat or slightly rising scale weight with measurable composition change is a desirable outcome on this protocol, not a failure.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.